Cheap Asthma Inhalers - Buy Asthma Inhalers online

Bolus Thrombolysis in Venous Thromboembolism (16)

Results
The results of the fibrinolysis experiments are shown in Figure 1. Saline produced 11% ±2% thrombolysis. Increasing doses of rt-PA produced increasing thrombolytic effects. The observed lysis rates were 24% ±3%, 41% ±3%, 66% ±6%, and 81% ±7% for the 4 increasing doses of rt-PA, respectively. These lysis rates would correspond to a final thrombus size of 267 |xg in saline-treated rabbits and sizes of 228, 177, 102, and 57 in rabbits treated with the 4 increasing doses of rt-PA. These results confirmed those obtained in previous experiments.
The results of the thrombus-growth studies obtained in different rabbits are shown in Figure 2. In saline-treated rabbits, 54 ±8 |xg of new radioactive fibrin accreted on the preformed experimental thrombi. In rabbits treated with the 4 increasing doses of bolus rt-PA, 51 ±6, 48±5, 39±6, and 28±4 |xg of new radioactive fibrin accreted on the thrombi, respectively. By combining the data from the fibrinolysis and thrombus-growth inhibition experiments obtained in 2 sets of animals, it is possible to assess the relative contribution of old and new fibrin in determining the final thrombus volume. In saline-treated rabbits, as much as 20.2% of the residual thrombi was due to fibrin newly accreted on the thrombi. In rabbits that received the 4 increasing bolus doses of rt-PA, the values were 22.3%, 27.1%, 38.2%, and 49.1%, respectively (Fig 3).

Figure-1

Figure 1. Thrombolytic effects of increasing bolus doses of rt-PA.

Figure-2

Figure 2. Effect of increasing bolus doses of rt-PA on the accretion of new fibrin on the preformed thrombi.

Figure-3

Figure 3. Relative proportion of preformed fibrin and fibrin newly accreted on the thrombi in determining final thrombus size after increasing bolus doses of rt-PA.

Category: Venous Thromboembolism

Tags: thrombolysis, thrombolytic agent, venous thromboembolism

printpage Print this Page

© 2011 - 2022 buy-asthma-inhalers-online.com. All rights reserved.